BCAX
BICARA THERAP (BCAX)
NASDAQ
$25.01+$0.45 (+1.85%)
Price as of Jun 23, 2026 4:10 PM EDT
  • $1.6B
    Market Cap
  • 167.43%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
Research and Development Expense
-18.7M
+127.26%
-8.2M
N/A
Depreciation and Amortization Expense
105,000
+87.50%
56,000
N/A
Total Operating Expenses
155.6M
+88.87%
82.4M
N/A
Operating Profit
-155.6M
+88.87%
-82.4M
N/A
Interest Income
17.9M
+22.56%
14.6M
N/A
Interest Expense
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
17.9M
+22.56%
14.6M
N/A
Total Nonoperating Income and Expense
17.9M
+22.56%
14.6M
N/A
Income before Taxes
-137.7M
+103.12%
-67.8M
N/A
Income Taxes
217,000
+20.56%
180,000
N/A
Extraordinary Items
0
N/A
0
N/A
Net Income
-137.9M
+102.88%
-68.0M
N/A
Net Income from Continuing Operations Applicable to Common
-137.7M
+103.12%
-67.8M
N/A
Basic EPS and Net Income
-2.52
-37.78%
-4.05
N/A
Diluted EPS and Net Income
-2.52
-37.78%
-4.05
N/A
Basic Weighted Average Shares
54.7B
+225.35%
16.8B
N/A
Diluted Weighted Average Shares
54.7B
+225.35%
16.8B
N/A
Balance Sheet
Cash and Cash Equivalents
96.7M
-80.26%
489.7M
N/A
Short-Term Investments
318.1M
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
414.8M
-15.30%
489.7M
N/A
Total Current Assets
422.1M
-16.01%
502.5M
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
330,000
+112.90%
155,000
N/A
Total Long-Term Assets
6.9M
+4.41%
6.6M
N/A
Total Assets
431.0M
-15.49%
510.0M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
Total Current Liabilities
28.9M
+60.92%
18.0M
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
593,000
N/A
0
N/A
Total Liabilities
29.5M
+63.03%
18.1M
N/A
Retained Earnings
-359.0M
+62.42%
-221.0M
N/A
Total Stockholders Equity
401.5M
-18.38%
491.9M
N/A
Total Shares Outstanding
56.6M
+3.97%
54.4M
N/A
Cash Flow
Cash from Operating Activities
-106.8M
+42.92%
-74.8M
N/A
Capital Expenditures
280,000
+294.37%
71,000
N/A
Cash from Investing Activities
-318.5M
+3,538,266.67%
-9,000
N/A
Dividends Paid
N/A
N/A
N/A
N/A
Cash from Financing Activities
32.3M
-90.34%
334.0M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
Return on Assets
-29.32%
N/A
N/A
N/A
Return on Equity
-30.88%
N/A
N/A
N/A
Revenue Growth
N/A
N/A
N/A
N/A
Current Ratio
14.58
N/A
N/A
N/A
Cash Ratio
3.34
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow